Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Compensation and benefits

Compensation and benefits at other companies

Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$11.27M-50.8%

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s compensation and benefits?
Citius Oncology, Inc. (CTOR) reported compensation and benefits of $3.53M in Q1 2026.
How has Citius Oncology, Inc.'s compensation and benefits changed year-over-year?
Citius Oncology, Inc.'s compensation and benefits increased by 68.9% year-over-year, from $2.09M to $3.53M.
What is the long-term trend for Citius Oncology, Inc.'s compensation and benefits?
Over 2 years (2023 to 2025), Citius Oncology, Inc.'s compensation and benefits has grown at a 105.7% compound annual growth rate (CAGR), from $1.97M to $8.32M.
What does compensation and benefits mean?
Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.